Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition

Elinore F. McCance‐Katz, Petrie M. Rainey, Gerald Friedland, Thomas R. Kosten, Peter JatlowAmerican 2001 · DOI

Abstract

Injection drug users are frequently infected with human immunodeficiency virus (HIV) and receive opioid dependence pharmacotherapies and zidovudine (ZDV), the latter as a component of highly active antiretroviral therapy. We previously reported that methadone substantially increases ZDV concentrations. We now report on oral ZDV pharmacokinetics in 52 subjects receiving the opioid dependence pharmacotherapies l-alpha-acetylmethadol LAAM, buprenorphine, or naltrexone, and 17 non-opioid-treated controls. Relative to the area under the time-concentration curve (AUC) of ZDV in control subjects, no statistically significant differences in ZDV AUC were observed in participants treated with LAAM (p = .75), buprenorphine (p = .37), or naltrexone (p = .34). While methadone maintenance may result in ZDV toxicity and possibly require dose adjustments, other opioid pharmacotherapies should not produce ZDV toxicity.
BibTeX
@inproceedings{mccancekatz2001effect,
  author = {Elinore F. McCance‐Katz and Petrie M. Rainey and Gerald Friedland and Thomas R. Kosten and Peter Jatlow},
  title = {{Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition}},
  booktitle = {American},
  year = {2001},
  doi = {10.1111/j.1521-0391.2001.tb00519.x},
}

Loading related content...

Figure